Bardoxolone
- CAS No.
- 218600-44-3
- Chemical Name:
- Bardoxolone
- Synonyms
- CDDO;CCDO;CS-321;RTA 401;Bardoxolone;RTA-401;RTA401;RTA 401|||CDDO;CDDO(Bardoxolone);Bardoxolone (CDDO);bardoxolone RTA 401
- CBNumber:
- CB72484825
- Molecular Formula:
- C31H41NO4
- Molecular Weight:
- 491.66
- MDL Number:
- MFCD07772296
- MOL File:
- 218600-44-3.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| CDDO ≥95% | 81035 | 1mg | $69 |
| CDDO ≥95% | 81035 | 5mg | $297 |
| CDDO ≥95% | 81035 | 10mg | $525 |
| Bardoxolone Asreported | 263638 | 5mg | $586 |
| Bardoxolone Asreported | 263638 | 10mg | $838 |
| More product size | |||
| Melting point | 180-182 °C |
|---|---|
| Boiling point | 632.9±55.0 °C(Predicted) |
| Density | 1.18 |
| storage temp. | Sealed in dry,Store in freezer, under -20°C |
| solubility | ≥49.2 mg/mL in DMSO; insoluble in H2O; ≥2.682 mg/mL in EtOH with gentle warming and ultrasonic |
| form | solid |
| pka | 4.52±0.70(Predicted) |
| color | White to yellow |
| InChIKey | TXGZJQLMVSIZEI-UQMAOPSPSA-N |
| SMILES | C1(=O)[C@@]([C@]2([C@](C)(C=C1C#N)C1[C@@]([C@]3([C@@](C(=O)C=1)([H])[C@]1([C@@](CC[C@](C1)(C)C)(C(O)=O)CC3)[H])C)(C)CC2)[H])(C)C |
| NCI Dictionary of Cancer Terms | CDDO |
| FDA UNII | 7HT68L8941 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501 | |||||||||
| NFPA 704 |
|
Bardoxolone price More Price(71)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 81035 | CDDO ≥95% | 218600-44-3 | 1mg | $69 | 2026-04-30 | Buy |
| Cayman Chemical | 81035 | CDDO ≥95% | 218600-44-3 | 5mg | $297 | 2026-04-30 | Buy |
| Cayman Chemical | 81035 | CDDO ≥95% | 218600-44-3 | 10mg | $525 | 2026-04-30 | Buy |
| Usbiological | 263638 | Bardoxolone Asreported | 218600-44-3 | 5mg | $586 | 2026-06-03 | Buy |
| Usbiological | 263638 | Bardoxolone Asreported | 218600-44-3 | 10mg | $838 | 2026-06-03 | Buy |
Bardoxolone Chemical Properties,Uses,Production
Chemical Properties
Tan Solid
Uses
Bardoxolone is a synthetic oleanane triterpenoid that exerts multifunctional activities in the control of cellular growth and differentiation. Bardoxolone is capable of activating the transcription fa ctor peroxisome proliferator activator receptor-γ (PPARγ), its apoptotic effects in malignant cells have been shown to occur independently of PPARγ. Bardoxolone was developed as an potential drug for the improvement of hyperglycemia, proteinuria, glomerulus structure, serum creatine, which may in turn be beneficial to treat diabetic kidney diseases, cancer and thromboembolic events.
Definition
ChEBI: Bardoxolone is a member of cyclohexenones.
Biological Activity
bardoxolone methyl, previously known as rta 402, is the lead molecule in reata's portfolio of antioxidant inflammation modulators (aims). the aims are potent inducers of the transcription factor nrf2, an important biological target that controls the production of many of the body's antioxidant and detoxification enzymes. because oxidative stress and inflammation occur throughout the course of chronic kidney disease (ckd) and are known to contribute to loss of kidney function, agents that activate the nrf2 pathway in patients with ckd may provide a novel method for preserving or improving kidney function. bardoxolone methyl is currently being investigated as a potential oral once-a-day treatment for ckd.
in vivo
Bardoxolone methyl(5, 10 mg/kg) decreased the percentage of caspase-3 immunopositive cells in a dose-dependent manner in rat kidney [3]. Bardoxolone methyl (0-10 mg/kg, i.p., a single dose) results in analgesia but not sedation in rats[4]. Bardoxolone methyl [10 mg/kg, twice-daily on day 21 after the first PAC (HY-B0015) injection] decreases PAC-induced levels of pNFκB and MCP-1 by increasing pNRf2 and HO-1 in rat DRG[4].
Bardoxolone Preparation Products And Raw materials
Raw materials
1of2
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32997 | 60 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19935 | 58 |
| CONIER CHEM AND PHARMA LIMITED | sales@conier.com | China | 49906 | 58 | |
| Zhengzhou Alfa Chemical Co.,Ltd | +86-18530059196 | sale04@alfachem.cn | China | 9636 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Finetech Industry Limited | +86-27-8746-5837 +86-18627785180 | info@finetechnology-ind.com | China | 9539 | 58 |
| Hefei Hirisun Pharmatech Co., Ltd | +8615056975894 | shawn@hirisunpharm.com | CHINA | 9897 | 58 |
| Labnetwork lnc. | +86-27-50766799 +86-18062016861 | contact@labnetwork.com | China | 19981 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 38999 | 58 |
| ShenZhen Trendseen Biological Technology Co.,Ltd. | 13417589054 | trendseenbio@gmail.com | China | 11674 | 58 |
View Lastest Price from Bardoxolone manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Bardoxolone
218600-44-3
|
$68.00-112.00 | 98.97% | 10g | TargetMol Chemicals Inc. |
-
- Bardoxolone
218600-44-3
- $68.00-112.00
- 98.97%
- TargetMol Chemicals Inc.
